IVIG Shows No Impact on VTE Risk in Dermatomyositis Patients

The rate of venous thromboembolism did not increase in dermatomyositis patients treated with intravenous immunoglobulin, compared with those not treated with IVIG.
MDedge News

source https://www.medscape.com/viewarticle/991881?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost